Martin & Co. Inc. TN Invests $924,000 in Abbott Laboratories $ABT

Martin & Co. Inc. TN acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,185 shares of the healthcare product maker’s stock, valued at approximately $924,000.

Other hedge funds have also added to or reduced their stakes in the company. W1M Asset Management Ltd bought a new position in Abbott Laboratories in the 2nd quarter worth about $590,000. Madison Wealth Partners Inc purchased a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $241,000. Varma Mutual Pension Insurance Co bought a new position in Abbott Laboratories in the second quarter worth approximately $28,588,000. Westpac Banking Corp purchased a new position in Abbott Laboratories during the 2nd quarter worth $1,091,000. Finally, TRB Wealth Management LLC bought a new stake in Abbott Laboratories during the 2nd quarter valued at $312,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $110.48 on Tuesday. The company has a market capitalization of $191.17 billion, a PE ratio of 35.75, a P/E/G ratio of 2.18 and a beta of 0.59. The company has a 50-day simple moving average of $103.06 and a two-hundred day simple moving average of $100.13. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period last year, the business earned $1.26 EPS. The company’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of recent research reports. Bank of America dropped their price target on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Piper Sandler restated an “overweight” rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. JPMorgan Chase & Co. lifted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, Citigroup boosted their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.